Med Life SA · BVB:M
Med Life SA — H1 2021 Earnings Presentation
36 slides from Med Life SA's earnings presentation, Sep 3, 2021
Slide 1: Investors and analysts presentation
Investors and analysts presentation 3 September 2021 Romania
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: MedLife at a glance
MedLife at a glance 1. Supportive market environment: expected - highest growth of healthcare market in CEE with a CAGR for private healthcare of 9.6% over 2018 – 2023 2. Leading private healthcare provider in Romania 3. One of the largest players in CEE 4. Balanced and highly synergic business mode
Slide 4: Agenda
About us • MedLife Medical System 1 • • How we grew MedLife network AGENDA • Sales structure Highlights 6m 2021 2 • Key messages 6m 2021 • Outlook • Sales and EBITDA evolution 2016-2020 Financial overview • Consolidated Statement of Profit and Loss 3 • • • Consolidated Statement of Financial Positio
Slide 5: Unique Revenue Capture Model - Flow of Referrals Among Business Lines
Unique Revenue Capture Model - Flow of Referrals Among Business Lines Hospitals Hyperclinics Maternities Clinics MedLife Stomatology ecosystem Laboratories Stem Cells Bank Pharmacies 5.5 million 5/ unique patients 1. About us 2. Highlights 2021 3. Financial overview
Slide 6: Introduction to MedLife Medical System
Introduction to MedLife Medical System Founded in 1996, MedLife is the leading private healthcare provider in Romania*. The Company operates the widest network of clinics, one of the largest networks of medical laboratories, mono and multidisciplinary hospitals and it has the largest client database
Slide 7: How we grew: Evolution
How we grew Evolution MedLife completed 2 First MedLife SGAM, part of Group Societe MedLife expands in The second large important Pharma hyperclinic is Generale, becomes a MedLife Hungary, acquiring acquisition was MedLife shares are transactions: a chain of 6 founded – MedLife shareholder; together
Slide 8: The chart below shows the Group's subsidiaries
The chart below shows the Group's subsidiaries 8/ 1. About us 2. Highlights 2021 3. Financial overview
Slide 9: How we grew: acquisitions so far
How we grew: 32 acquisitions so far Most significant acquisitions completed include: 1. PDR Group in Brasov ( 83.01% ownership) – multidisciplinary hospital, outpatient units and labs; 2. Genesys Grup in Arad (73% ownership) - multidisciplinary hospital, outpatient units and labs; 3. Sama Medical Ce
Slide 10: MedLife in Romania – CEE expansion
No. 1 in Romania – CEE expansion Legend: Hospitals Maternities Hyperclinics Hungary Pharmacies Stomatology Centers Laboratories Clinics Romania 10 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 11: MedLife outpatient units
MedLife outpatient units MedLife Clinics Hyperclinics One stop shop concept - MedLife hyperclinics include medical outpatient Stomatology Centers specialties, providing in one single place clinical examinations and imaging. x2 High performance imaging investigations: MedLife Excellence radiology, DE
Slide 12: Stomatology Centers
Stomatology Centers PRFG technology It allows rapid healing after dental interventions with high degree of complexity, in just a few minutes. MedLife Clinics DENT ESTET by MedLife, the only dental Stomatology network in Romania specialized in Centers orthodontic services by age segments: 11 medical
Slide 13: MedLife Hospitals
MedLife Hospitals The largest network of private hospitals in Romania, with >900 beds MedLife Multidisciplinary Inpatient units Clinics MedLife Genesys Hospital, Arad MedLife PDR Hospital, Brasov Stomatology Lotus Hospital, Ploiești Centers Humanitas Hospital, Cluj Napoca Polisano Hospitals, Sibiu M
Slide 14: MedLife Maternities and Stem Cells Bank
MedLife Maternities and Stem MedLife Grivita Maternity is the first private maternity hospital in Cells Bank Bucharest accredited by UNICEF as Baby-Friendly Hospital MedLife Clinics Polisano Maternity, Sibiu MedLife Genesys Maternity, Arad Stomatology Centers Maternities have birth blocks consisting
Slide 15: MedLife Laboratories
MedLife Laboratories MedLife Hyperclinics The latest laboratory technologies by Abbott. MedLife Clinics Stomatology Centers The largest network of private laboratories in Romania 2 Full range of tests performed from MedLife Excellence standard blood tests to complex genetic Centers analysis Partners
Slide 16: MedLife Pharmacies: PharmaLife
MedLife Pharmacies: MedLife Own laboratory, where clients can Hyperclinics PharmaLife benefit from specific products. MedLife Clinics Stomatology Centers NHIH contracts for free and subsidized prescriptions MedLife Excellence Centers Clickpharm.ro website for online shopping MedLife Hospitals Pharma
Slide 17: Highlights 6m2021
Highlights 6m2021 • Sales structure • Key developments 6m2021 • Outlook 2 17 /
Slide 18: MedLife Business lines and Sales Structure
MedLife Business lines and Sales Structure More than 730,000 employees benefiting from MedLife healthcare prevention packages 18 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 19: Source of funding
Source of funding Source of funding by business line 19 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 20: Key messages 6m 2021
Key messages 6m 2021 ➢ Pro-forma Sales of RON 741m RON in 6m 2021, increase by 57.8% compared to 6m 2020; ➢ IFRS Sales for 6m 2021 of 677.3m RON, increased by 44.2% compared to 6m 2020 (42.4% like to like increase); ➢ Strong operating performance, in line with the strategy of recent years: -- 21.2%
Slide 21: Key messages 6m 2021 (Cont.)
Key messages 6m 2021 (Cont.) ➢ Clinics: focused on the development of new products in outpatient units, from pre & post covid screening packages to prevention packages for patients with chronic pathology. Revenue increased by 36.6% vs. 6m 2020, with 29.6% increase in traffic and 5.4% increase in ave
Slide 22: Key messages 6m 2021 (Cont.)
Key messages 6m 2021 (Cont.) ➢ Corporate: developed dedicated programs for the corporate segment, as employers become more and more concerned about the health of their employees; 10.4% increase in revenue, with a portfolio of subscriptions higher by 8% as compared to 6m 2020 (730k HPP). ➢ Pharmacies
Slide 23: Operational KPIs – supporting annex for BL evolution
Operational KPIs – supporting annex for BL evolution 23 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 24: Key messages 6m 2021 (Cont.)
Key messages 6m 2021 (Cont.) ➢ First 6 months of 2021 marked the increase of existing facilities by 40 million euros by signing a syndicated loan in total amount of approximately 143 million euros + additional 50 million euros submitted to approval to shareholders: a total of 90 million euros funds
Slide 25: Outlook
Outlook Main development segments include: 1. M&A and digitization programs will be a priority in the strategy plan; We have completed the acquisition of CED Pharma and Pharmachem Distribution and we are in advanced discussions for other acquisitions. We believe that by the end of this year we will
Slide 26: Financial overview
Financial overview Sales and EBITDA evolution 2016-2020 Consolidated Statement of Profit and Loss 6m 2021 Consolidated Statement of Financial Position 30 June 2021 Consolidated Statement of Cash Flow 6m 2021 3 26 /
Slide 27: Sales and EBITDA evolution 2016-2020
Sales and EBITDA evolution 2016-2020 1,213,495 967,380 794,563 623,220 502,987 27 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 28: Sales and EBITDA evolution 2016-2020
Sales and EBITDA evolution 2016-2020 28 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 29: Consolidated Statement of Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) 29 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 30: Consolidated Statement of Profit and Loss (2/3) explained
Consolidated Statement of Profit and Loss (2/3) explained 1) 6m 2021 Pro-forma vs. 6m 2020 IFRS ❑ Sales increased by 57.8%, to 741m RON ❑ OPEX increased by 45.5%, to 640.7m RON ❑ More than threefold increase in EBIT, to 103.8m RON, leading to 14.0% margin (6.6% in the same period last year), due to
Slide 31: Consolidated Statement of Profit and Loss (3/3)
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution Release of 5.9 p.p. in EBITDA margin due to: ➢ Increase in Consumable & repair materials with 1.9 p.p. of Sales due to reagents and materials related to PCR testing; ➢ Decrease in Commodities with 1.2 p.p. of Sales: decrease of Pharmacie
Slide 32: Consolidated Statement of Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) 32 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 33: Consolidated Statement of Financial Position (2/2)
Consolidated Statement of Financial Position (2/2) Debt position 33 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 34: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by good operating performance: 1. two folded increase in net cash from operating activities; 2. 156% increase in cash used in investing activities; 3. Cash used in financing activities of 8m RON 34 / 1. About us 2. Highlights
Slide 35: Annexes
Annexes 35 / 1. About us 2. Highlights 2021 3. Financial overview
Slide 36: Annexes
Annexes 36 / 1. About us 2. Highlights 2021 3. Financial overview